Skip to main content
Erschienen in: Journal of Neurology 6/2017

17.04.2017 | Original Communication

Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study

verfasst von: Arianna Sartori, Mohammad Abdoli, Mark S. Freedman

Erschienen in: Journal of Neurology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Benign multiple sclerosis (MS) is a discussed clinical entity, with variable reported prevalence (6–64%) requiring at least 5–10 years of clinical observation. Moreover, many benign patients progress with time becoming no longer benign (NLB). The objective of this study is to compare benign MS patients (EDSS ≤3, 10 years from disease onset) who still fulfilled the definition at 20 years to those NLB. In our retrospective study based on Ottawa Hospital MS Clinic database, 175 benign patients fulfilled the inclusion criteria (clinically definite MS, EDSS ≤3 at 10 years, disease onset from 1983 to 1993, and clinical assessments performed at 10 ± 1 and 20 ± 1 years from onset). Out of the identified patients, 66.3% remained benign at 20 years; however, by changing the definition for benign to EDSS ≤2 or ≤1 at 10 years, they increased to 71.9 and 81.6%, respectively. Female sex, EDSS ≤1 at 10 years, and a pure sensory onset were associated with a benign course, while a pure motor onset with an NLB condition. According to multivariate analysis, an EDSS ≤2 at 10 years predicted a long-term benign course. Our study questions the current definition of “benign” MS, suggesting a more stringent EDSS cutoff at 10 years to predict long-term benign prognosis.
Literatur
1.
Zurück zum Zitat McAlpine D (1961) The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and followed up until the tenth year or more of the disease. Brain 84:186–203CrossRefPubMed McAlpine D (1961) The benign form of multiple sclerosis. A study based on 241 cases seen within 3 years of onset and followed up until the tenth year or more of the disease. Brain 84:186–203CrossRefPubMed
2.
Zurück zum Zitat Kurtzke JF, Beebe GW, Nagler B et al (1977) Studies on the natural history of multiple sclerosis VIII. Early prognostic features of the later course of the illness. J Chron Dis 30:819–830CrossRefPubMed Kurtzke JF, Beebe GW, Nagler B et al (1977) Studies on the natural history of multiple sclerosis VIII. Early prognostic features of the later course of the illness. J Chron Dis 30:819–830CrossRefPubMed
3.
Zurück zum Zitat Poser S, Wikström J, Bauer HJ (1979) Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 40:159–168CrossRefPubMed Poser S, Wikström J, Bauer HJ (1979) Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 40:159–168CrossRefPubMed
4.
Zurück zum Zitat Thompson AJ, Hutchinson M, Brazil J et al (1986) A clinical and laboratory study of benign multiple sclerosis. QJM 225:69–80 Thompson AJ, Hutchinson M, Brazil J et al (1986) A clinical and laboratory study of benign multiple sclerosis. QJM 225:69–80
5.
Zurück zum Zitat Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911CrossRefPubMed Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911CrossRefPubMed
6.
Zurück zum Zitat Ramsaransing GS, De Keyser J (2006) Benign course in multiple sclerosis: a review. Acta Neurol Scand 113:359–369CrossRefPubMed Ramsaransing GS, De Keyser J (2006) Benign course in multiple sclerosis: a review. Acta Neurol Scand 113:359–369CrossRefPubMed
7.
Zurück zum Zitat Ramsaransing GSM, De Keyser J (2007) Predictive value of clinical characteristics for benign multiple sclerosis. Eur J Neurol 14:885–889CrossRefPubMed Ramsaransing GSM, De Keyser J (2007) Predictive value of clinical characteristics for benign multiple sclerosis. Eur J Neurol 14:885–889CrossRefPubMed
8.
Zurück zum Zitat Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 68:496–500CrossRefPubMed Sayao AL, Devonshire V, Tremlett H (2007) Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology 68:496–500CrossRefPubMed
9.
Zurück zum Zitat Costelloe L, Thompson A, Walsh C et al (2008) Long-term clinical relevance of criteria designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 79:1245–1248CrossRefPubMed Costelloe L, Thompson A, Walsh C et al (2008) Long-term clinical relevance of criteria designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 79:1245–1248CrossRefPubMed
10.
Zurück zum Zitat Glad SB, Nyland HI, Aarseth JH et al (2009) Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Mult Scler 15:942–950CrossRefPubMed Glad SB, Nyland HI, Aarseth JH et al (2009) Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Mult Scler 15:942–950CrossRefPubMed
11.
Zurück zum Zitat Leray E, Coustans M, Le Page E et al (2013) ‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. Mult Scler 19:458–465CrossRefPubMed Leray E, Coustans M, Le Page E et al (2013) ‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study. Mult Scler 19:458–465CrossRefPubMed
12.
Zurück zum Zitat Pittock SJ, McClelland RL, Mayr WT et al (2004) Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 56:303–306CrossRefPubMed Pittock SJ, McClelland RL, Mayr WT et al (2004) Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 56:303–306CrossRefPubMed
13.
Zurück zum Zitat Hirst C, Ingram G, Swingler R et al (2008) Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry 79:1137–1143CrossRefPubMed Hirst C, Ingram G, Swingler R et al (2008) Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. J Neurol Neurosurg Psychiatry 79:1137–1143CrossRefPubMed
14.
Zurück zum Zitat Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904CrossRefPubMed Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904CrossRefPubMed
15.
Zurück zum Zitat Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357:1576–1582CrossRefPubMed Comi G, Filippi M, Barkhof F et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357:1576–1582CrossRefPubMed
16.
Zurück zum Zitat Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology 67:1242–1249CrossRefPubMed Kappos L, Polman CH, Freedman MS et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology 67:1242–1249CrossRefPubMed
17.
Zurück zum Zitat Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511CrossRefPubMed Comi G, Martinelli V, Rodegher M et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511CrossRefPubMed
18.
Zurück zum Zitat Freedman MS, Comi G, De Stefano N et al (2014) Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord 3:147–155CrossRefPubMed Freedman MS, Comi G, De Stefano N et al (2014) Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord 3:147–155CrossRefPubMed
19.
Zurück zum Zitat Freedman MS (2013) Present and Emerging Therapies for Multiple Sclerosis. Continuum (Minneap Minn) 19:968–991 Freedman MS (2013) Present and Emerging Therapies for Multiple Sclerosis. Continuum (Minneap Minn) 19:968–991
20.
Zurück zum Zitat Oh J, O’Connor PW (2015) Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol 28:230–236CrossRefPubMed Oh J, O’Connor PW (2015) Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol 28:230–236CrossRefPubMed
21.
Zurück zum Zitat Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMed Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMed
22.
Zurück zum Zitat Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMed Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58:840–846CrossRefPubMed
23.
Zurück zum Zitat Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentral Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Joseph FG, Hirst CL, Pickersgill TP et al (2009) CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 80:292–296CrossRefPubMed Joseph FG, Hirst CL, Pickersgill TP et al (2009) CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 80:292–296CrossRefPubMed
25.
Zurück zum Zitat Portaccio E, Stromillo ML, Goretti B et al (2009) Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology 73:498–503CrossRefPubMed Portaccio E, Stromillo ML, Goretti B et al (2009) Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology 73:498–503CrossRefPubMed
26.
Zurück zum Zitat Perini P, Tagliaferri C, Belloni M et al (2001) The HLA-DR13 haplotype is associated with benign multiple sclerosis in northeast Italy. Neurology 57:158–159CrossRefPubMed Perini P, Tagliaferri C, Belloni M et al (2001) The HLA-DR13 haplotype is associated with benign multiple sclerosis in northeast Italy. Neurology 57:158–159CrossRefPubMed
27.
Zurück zum Zitat Amato MP, Zipoli V, Goretti B et al (2006) Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 253:1054–1059CrossRefPubMed Amato MP, Zipoli V, Goretti B et al (2006) Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 253:1054–1059CrossRefPubMed
28.
Zurück zum Zitat Calabrese M, Favaretto A, Poretto V et al (2013) Low degree of cortical pathology is associated with benign course of multiple sclerosis. Mult Scler 19:904–911CrossRefPubMed Calabrese M, Favaretto A, Poretto V et al (2013) Low degree of cortical pathology is associated with benign course of multiple sclerosis. Mult Scler 19:904–911CrossRefPubMed
Metadaten
Titel
Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study
verfasst von
Arianna Sartori
Mohammad Abdoli
Mark S. Freedman
Publikationsdatum
17.04.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8487-y

Weitere Artikel der Ausgabe 6/2017

Journal of Neurology 6/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.